SS-31 (Elamipretide)
- Category
- Longevity & Anti-Aging
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
A mitochondria-targeted peptide marketed to reverse age-related decline in cellular energy, heart, muscle, eye, and kidney function. It stabilizes cardiolipin, and human evidence gives medium confidence to improved ATP production, while cardiac, muscle, retinal, and kidney benefits rest on thin, low-confidence trials. Injection reactions are common and pregnancy safety unknown. On September 19, 2025, the FDA granted Forzinity (elamipretide) accelerated approval only for muscle strength in Barth syndrome, a rare mitochondrial disease, in patients weighing at least 30 kg. Aging and wellness uses are unapproved, and products sold online outside the approved drug are unregulated.
Read Full recordStudied uses & evidence
Studied uses(6)
Reversal of age-related mitochondrial dysfunction and improved ATP production
MediumSmall human trial showed improved muscle ATP production, backed by extensive animal data.
Reversal of age-related cardiac diastolic dysfunction
LowReversed diastolic dysfunction in aged mice across several studies, not tested in aging humans.
Improved skeletal muscle performance and exercise tolerance during aging
LowAnimal studies show improved muscle energetics, but a human trial missed the exercise function endpoint.
Evidence limits
- Evidence Level
- Phase 2-3
SS-31's clinical evidence is the most extensive of any mitochondria-targeted peptide. The TAZPOWER trial in Barth syndrome (Phase 2/3 with 168-week open-label extension, 12 patients) achieved FDA accelerated approval based on >45% improvement in knee extensor muscle strength and sustained improvements in 6MWT, cardiac function, and fatigue scores. The MMPOWER-3 trial (218 PMM patients, Phase 3) failed co-primary endpoints but revealed a significant 6MWT improvement in the nDNA variant subgroup, suggesting elamipretide is effective when ETC protein subunits are structurally normal but membrane organization is disrupted. The ReCLAIM-2 trial (176 dry AMD patients, Phase 2) did not meet primary endpoints but showed 43-47% reduction in ellipsoid zone attenuation progression and improved low-light vision. The PROGRESS-HF trial (71 HFrEF patients, Phase 2) and EMBRACE-STEMI trial (STEMI patients, Phase 2a) failed primary endpoints. Roshanravan et al. 2021 (39 older adults, RCT) demonstrated improved mitochondrial ATP production after a single dose. The preclinical evidence base is exceptionally strong, with consistent reversal of age-related mitochondrial dysfunction across cardiac, skeletal muscle, renal, and retinal models in aged mice.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Severe renal impairment
ModerateRenal-impairment pharmacokinetics have been characterized. Severe renal impairment increases exposure; dialysis has not been studied.
General cautions
Pregnancy
AbsolutePregnancy — human safety data are unavailable; animal reproductive studies found no adverse developmental outcomes at tested exposures. Pregnancy is not an absolute contraindication. The labeled contraindication is serious hypersensitivity to elamipretide or FORZINITY excipients.
Risk summary(7)
Risks = level of concern: High · Moderate · Low · Theoretical
Injection site reactions
HighHypersensitivity reactions
ModerateHeadache, dizziness, nausea, abdominal pain, and fatigue
LowRenal excretion considerations
ModerateBenzyl alcohol preservative in FORZINITY formulation
ModeratePregnancy and lactation safety unknown
ModerateUnregulated products sold online: purity and IP concerns
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.